BioReliance Corp. has partnered with Gentronix to offer their GreenScreen HC in vitro assay as part of its genotoxicity screening services. GreenScreen HC, in conjunction with Ames II assays, allows pharmaceutical companies to test for genotoxic potential earlier in the preclinical development process, using only a few milligrams of test compound, according to the company. John Nicholson, chairman and chief executive officer of Gentronix, said, “We are delighted to complete this agre...